Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Expert Opin Investig Drugs. 2009 Jul;18(7):957–971. doi: 10.1517/13543780903002074

Figure 2. Proteasome inhibition by several compounds used in clinical trials.

Figure 2

β subunits of the proteasome have three catalytic sites: β1 (associated with caspase-like activity), β2 (associated with trypsin-like activity), and β5 (associated with chymotrypsin-like activity). Compounds in clinical trials could preferentially inhibit β5 chymotryptic site of the proteasome.